Gastroesophageal Reflux (GER)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Smell/Taste diseases

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 57 12 74 29 13 6 44 15
Gastroesophageal Reflux Disease 57 12 36 54 15 17 71
Gerd 57 12 42
Gerd - Gastro-Esophageal Reflux Disease 12
Gastroesophageal Reflux Disease; Gerd 57
Gastroesophageal Reflux, Pediatric 57
Gastro-Esophageal Reflux 12
Gastresophageal Reflux 12
Acid Reflux 12
Ger 57



57 (Updated 05-Mar-2021)
autosomal dominant


gastroesophageal reflux:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:8534
OMIM® 57 109350
KEGG 36 H01602
ICD9CM 34 530.81
MeSH 44 D005764
NCIt 50 C26781
SNOMED-CT 67 235595009
ICD10 32 K21.9
MedGen 41 C0017168
UMLS 71 C0017168

Summaries for Gastroesophageal Reflux

KEGG : 36 Gastro-oesophageal reflux disease (GERD) is a condition in which reflux of the stomach contents into the oesophagus results in symptoms or, occasionally, complications. GERD can be classified as non-erosive reflux disease (NERD) or erosive reflux disease (ERD) based on the presence or absence of esophageal mucosal damage seen on endoscopy. ERD can manifest in a wide range of symptoms which can be subdivided into typical, atypical, and extraesophageal symptoms. Typical symptoms include heartburn and acid regurgitation which have high specificity but low sensitivity for GERD. Atypical symptoms such as epigastric pain, dyspepsia, nausea, bloating, and belching may be suggestive of GERD but may overlap with other conditions in the differential diagnosis. Lastly, there are various extraesophageal symptoms including chronic cough, asthma, laryngitis, and dental erosions. In a small but important minority, complications of peptic oesophagitis may occur including oesophageal strictures, Barrett's oesophagus, and rarely oesophageal adenocarcinoma. Hiatus hernia is statistically associated with GERD, the presence of which is relevant to surgical treatment. The diagnosis is typically made by a combination of clinical symptoms, response to acid suppression, as well as objective testing with upper endoscopy and esophageal pH monitoring. GERD is a chronic disease that typically requires long term management in the form of lifestyle modification, medical therapy and, for a subset of patients, surgical therapy. The mainstay of treatment is acid suppression which can be achieved with several classes of medications including antacids, histamine-receptor antagonists (H2RAs), or proton-pump inhibitors (PPIs).

MalaCards based summary : Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to hernia, hiatus and esophagitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastroesophageal Reflux is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Senescence and Autophagy in Cancer and Gastric acid production. The drugs Dopamine and Domperidone have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and liver, and related phenotypes are gastroesophageal reflux and esophagitis

OMIM® : 57 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350) (Updated 05-Mar-2021)

MedlinePlus : 42 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Wikipedia : 74 Gastroesophageal reflux disease (GERD), is a chronic condition in which stomach contents rise up into... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 638)
# Related Disease Score Top Affiliating Genes
1 hernia, hiatus 33.0 MLN HRH2 GAST CYP2C19
2 esophagitis 32.8 TP53 IL1B HRH2 GAST CYP2C19 CXCL8
3 peptic esophagitis 32.7 MLN IL1B HRH2 GAST CYP2C19 CXCL8
4 gastroparesis 32.5 MLN GAST CCK
5 helicobacter pylori infection 32.1 IL1B CYP2C19 CXCL8
6 gastritis 31.9 TP53 IL1B HRH2 GAST CYP2C19 CXCL8
7 peptic ulcer disease 31.9 TP53 IL1B HRH2 GAST CYP2C19 CXCL8
8 dyskinesia of esophagus 31.8 MLN HRH2 CCL26
9 irritable bowel syndrome 31.8 PYY MLN IL1B CXCL8 CCK
10 bile reflux 31.8 MLN GAST CCK
11 duodenal ulcer 31.6 MLN IL1B HRH2 GAST CYP2C19 CXCL8
12 atrophic gastritis 31.6 TP53 IL1B GAST CXCL8
13 otitis media 31.5 IL1B CXCL8 ACTL6A
14 constipation 31.5 PYY MLN GCG GAST CHAT CCK
15 duodenogastric reflux 31.5 PYY MLN GAST CCK
16 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.5 HRH2 GAST
17 systemic scleroderma 31.5 MLN HRH2 GAST CCK
18 apnea, obstructive sleep 31.5 IL1B GCG CXCL8
19 gastrointestinal system disease 31.4 MLN GCG GAST CCK
20 dumping syndrome 31.3 PYY MLN GCG GAST CCK
21 gastric ulcer 31.3 TP53 IL1B HRH2 GAST CYP2C19 CXCL8
22 body mass index quantitative trait locus 11 31.2 TP53 PYY MLN IL1B GCG CXCL8
23 sleep disorder 31.2 IL1B GCG CXCL8
24 volvulus of midgut 31.2 PYY MLN GCG
25 aspiration pneumonitis 31.2 HRH2 CXCL8
26 ileus 31.1 MLN IL1B CCK
27 diabetes mellitus 31.1 TP53 PYY MLN IL1B GCG GAST
28 gastroduodenitis 31.1 GAST CCL26
29 diarrhea 31.0 PYY MLN IL1B HRH2 GAST CXCL8
30 type 2 diabetes mellitus 31.0 TP53 PYY IL1B GCG GAST CYP2C19
31 celiac disease 1 31.0 PYY IL1B GCG GAST CXCL8 CCK
32 autonomic neuropathy 31.0 MLN GCG GAST CCK
33 zollinger-ellison syndrome 30.9 MLN HRH2 GAST
34 peripheral nervous system disease 30.9 TP53 IL1B GCG CXCL8 CHAT
35 eating disorder 30.8 PYY GCG CCK
36 tracheitis 30.8 IL1B CXCL8
37 hyperglycemia 30.8 PYY GCG CCK ABCC8
38 active peptic ulcer disease 30.7 HRH2 CYP2C19
39 gastroenteritis 30.7 PYY MLN IL1B HRH2 CXCL8
40 common cold 30.5 IL1B CXCL8 CCL26
41 lichen planus 30.5 TP53 IL1B CXCL8
42 gallbladder disease 30.5 TP53 PYY MLN CCK
43 diabetic autonomic neuropathy 30.5 MLN GCG GAST
44 bronchial disease 30.5 IL1B CXCL8 CCL26
45 short bowel syndrome 30.5 PYY GCG GAST CCK
46 disease of mental health 30.0 TP53 RPS6KA3 PYY IL1B HRH2 GCG
47 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 11.7
48 barrett esophagus 11.6
49 spastic paraplegia 9a, autosomal dominant 11.5
50 neuropathy, hereditary sensory and autonomic, type iia 11.3

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 12)

Acute Cystitis Anxiety
Bronchitis Deficiency Anemia
Dyskinesia of Esophagus Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:

Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Human phenotypes related to Gastroesophageal Reflux:

# Description HPO Frequency HPO Source Accession
1 gastroesophageal reflux 31 HP:0002020
2 esophagitis 31 HP:0100633
3 barrett esophagus 31 HP:0100580

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
G I:
gastroesophageal reflux
chronic ulcerating esophagitis

columnar epithelium-lined distal esophagus

adenocarcinoma of the esophagus risk about 10%

Clinical features from OMIM®:

109350 (Updated 05-Mar-2021)

UMLS symptoms related to Gastroesophageal Reflux:

nausea and vomiting, constipation, abdominal pain, diarrhea, dyspepsia, icterus, heartburn, gastrointestinal gas

Drugs & Therapeutics for Gastroesophageal Reflux

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
Trimebutine Approved Phase 4 39133-31-8
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Clozapine Approved Phase 4 5786-21-0 2818
Lithium carbonate Approved Phase 4 554-13-2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Ziprasidone Approved Phase 4 146939-27-7 60854
Nortriptyline Approved Phase 4 72-69-5 4543
Calcium polycarbophil Approved Phase 4 126040-58-2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
tannic acid Approved Phase 4 1401-55-4
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
Clarithromycin Approved Phase 4 81103-11-9 84029
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Rebamipide Approved, Investigational Phase 4 90098-04-7
Ethanol Approved Phase 4 64-17-5 702
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Maleic acid Experimental Phase 4 110-16-7 444266
Polaprezinc Experimental Phase 4 107667-60-7
28 Indobufen Investigational Phase 4 63610-08-2
29 Dopamine Agents Phase 4
30 Dopamine Antagonists Phase 4
31 Antiemetics Phase 4
32 Gastrins Phase 4
33 Cytochrome P-450 CYP3A Inhibitors Phase 4
34 Antipsychotic Agents Phase 4
35 Parasympatholytics Phase 4
36 Psychotropic Drugs Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Psyllium Phase 4
40 Protective Agents Phase 4
41 Hormones Phase 4
42 Hormone Antagonists Phase 4
43 TEMPO Phase 4
44 Aluminum hydroxide, magnesium hydroxide, simethicone drug combination Phase 4
45 Antioxidants Phase 4
46 Acidophilus Phase 4
47 Hallucinogens Phase 4
48 Cathartics Phase 4
49 Laxatives Phase 4
50 Omega 3 Fatty Acid Phase 4

Interventional clinical trials:

(show top 50) (show all 867)
# Name Status NCT ID Phase Drugs
1 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
2 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Unknown status NCT02934152 Phase 4 H pylori eradication
3 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
4 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
5 Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial. Unknown status NCT01782118 Phase 4
6 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
7 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
8 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
9 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
10 A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
11 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
12 A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications Unknown status NCT02213887 Phase 4 Pantoprazole;Pantoprazole
13 Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation Unknown status NCT03355170 Phase 4 Lansoprazole
14 A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD Completed NCT00410592 Phase 4 Esomeprazole 40mg;Pantoprazole 40mg;Lansoprazole 30mg
15 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
16 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
17 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
18 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
19 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00574925 Phase 4 Esomeprazole
20 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
21 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
22 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment Completed NCT00242736 Phase 4 Esomeprazole
23 An Open, Randomized, Two-way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD). Completed NCT00635414 Phase 4 Esomeprazole;Esomeprazole
24 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
25 A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks. Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
26 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
27 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
28 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
29 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
30 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Completed NCT02505945 Phase 4 Omeprazole
31 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
32 A Randomized, Open, Parallel-group, Multi-national, Multi-centre, Phase IV Study to Evaluate the Efficacy of Three Different Patient Management Strategies With and Without Esomeprazole 20 mg During a 3 Months Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related Completed NCT00343161 Phase 4 esomeprazole;Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
33 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
34 Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI. Completed NCT00251732 Phase 4 Standard dose (once daily) PPI plus low-dose antidepressant;Double dose PPI plus evening placebo;Rabeprazole , placebo, placebo
35 Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
36 The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia. Completed NCT00287391 Phase 4 Rabeprazole
37 Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease. Completed NCT00184522 Phase 4 Aflurax;esomeprazole
38 RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Completed NCT01503476 Phase 4
39 Effect of Citalopram on Fasting and Postprandial Lower Esophageal Sphincter Function in Healthy Subjects: a Double-blind, Placebo-controlled, Randomized, Cross-over Study Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
40 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
41 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
42 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
43 A Pilot Study Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole 60 mg and Esomeprazole 40 mg for Gastroesophageal Reflux Disease Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
44 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
45 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
46 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
47 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
48 Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
49 Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity Completed NCT03037606 Phase 4 Rabelis DDR 50 mg Capsules;Pariet 20 mg Enteric Coated Tablets
50 A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI) Completed NCT00384592 Phase 4 Esomeprazole

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Bethanechol Chloride
Calcium Carbonate
Calcium gluceptate
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Isosorbide Dinitrate
Isosorbide Mononitrate
magnesium carbonate
Magnesium Hydroxide
magnesium trisilicate
Metoclopramide Hydrochloride
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Pantoprazole sodium
Sodium Bicarbonate

Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 29

Anatomical Context for Gastroesophageal Reflux

MalaCards organs/tissues related to Gastroesophageal Reflux:

Lung, Heart, Liver, Bone, Skin, Tongue, Brain

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 18970)
# Title Authors PMID Year
Fine mapping a gene for pediatric gastroesophageal reflux on human chromosome 13q14. 57 61
15014979 2004
Refined localization of a gene for pediatric gastroesophageal reflux makes HTR2A an unlikely candidate gene. 57 61
11140952 2000
Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14. 61 57
10891964 2000
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. 57 61
10080844 1999
Gastroesophageal Reflux Disease. 42 61
33351044 2020
Gastroesophageal Reflux Disease: A Review. 42 61
33351048 2020
Effects of Chaihu-Shugan-San for reflux esophagitis: A protocol for systematic review and meta-analysis. 42
33285744 2020
Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers. 54 61
18924018 2008
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. 61 54
17559380 2007
Gastric emptying of glucose solution and associated plasma concentrations of GLP-1, GIP, and PYY before and after fundoplication. 61 54
17200910 2007
Helicobacter pylori infection is the major risk factor for gastric inflammation in the cardia. 54 61
16602036 2006
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 61 54
17006979 2006
[Roles of bile and gastrin in the pathogenesis of childhood gastroesophageal reflux disease]. 61 54
16923358 2006
The transient receptor potential vanilloid 1: role in airway inflammation and disease. 54 61
16464449 2006
Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. 54 61
16287506 2005
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. 61 54
15683433 2005
Edkins and a century of acid suppression. 54 61
16172550 2005
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. 61 54
15585388 2004
The relationship between the esophageal tissue content of neurotensin and the presence or absence of esophageal inflammation. 54 61
14992433 2004
Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. 61 54
12907324 2003
[A study on the relationship of Helicobacter pylori, gastrin and gastroesophageal reflux disease]. 61 54
12812673 2003
[Modern aspects of treating gastroesophageal reflux disease]. 61 54
12664775 2003
Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. 54 61
12452391 2002
The effect of cholecystectomy on plasma cholecystokinin. 61 54
12358231 2002
Effects of adjustable gastric banding on altered gut neuropeptide levels in morbidly obese patients. 61 54
11775572 2001
The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease. 54 61
11569682 2001
Restoration of enamel and dentin erosion due to gastroesophageal reflux disease: a case report. 61 54
11402771 2001
Alterations of gut neuropeptides in gastroesophageal reflux disease are resolved after antireflux surgery. 54 61
11182403 2000
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. 61 54
10872661 2000
Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. 54 61
9721157 1998
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. 54 61
9626024 1998
Prolongation of the QT interval related to cisapride-diltiazem interaction. 54 61
9545159 1998
Effect of gastrin-17 on lower esophageal sphincter characteristics in man. 61 54
9440634 1997
Effects of gastroesophageal reflux on the oral cavity. 61 54
9422634 1997
The role of motilin and cisapride in the enteric nervous system of the lower esophageal sphincter in humans. 54 61
9413048 1997
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance. 61 54
9165690 1996
Gastroesophageal reflux disease is associated with enteric hormone abnormalities. 54 61
8311131 1994
Incidence of gastroesophageal reflux with casein and whey-based formulas. 61 54
8350205 1993
Nonulcer dyspepsia: current approaches to diagnosis and management. 61 54
8480563 1993
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. 61
33585034 2021
Gastroesophageal Reflux Disease - Health-Related Quality of Life Questionnaire: prospective development and validation in Italian. 61
32925505 2021
The Relationship Between Otitis Media With Effusion and Gastroesophageal Reflux Disease: A Meta-analysis. 61
33555743 2021
A transformational change in scintigraphic gastroesophageal reflux studies: A comparison with historic techniques. 61
33155748 2021
Overlapping Symptoms of Gastroesophageal Reflux and Aspiration Highlight the Limitations of Validated Questionnaires. 61
33264182 2021
Continuous Glucose Monitoring to Diagnose Hypoglycemia Due to Late Dumping Syndrome in Children After Gastric Surgeries. 61
33506160 2021
Comparing short-term patient outcomes after fundoplication performed over a traditional bougie versus a functional lumen imaging probe. 61
32919782 2021
Risk factors for postoperative ileus after oblique lateral interbody fusion: a multivariate analysis. 61
33031922 2021
Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells. 61
33261858 2021
Acupuncture and Related Therapies for the Treatment of Gastrointestinal Diseases. 61
33116064 2021
Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease. 61
32068153 2021

Variations for Gastroesophageal Reflux

ClinVar genetic disease variations for Gastroesophageal Reflux:

6 (show all 15)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHAT NM_020549.4(CHAT):c.1061C>T (p.Thr354Met) SNV Pathogenic 523528 rs769234940 10:50835781-50835781 10:49627735-49627735
2 CHAT NM_020549.4(CHAT):c.2081C>G (p.Ser694Cys) SNV Pathogenic 523529 rs201439531 10:50872926-50872926 10:49664880-49664880
3 ASIC4-AS1 NM_013335.4(GMPPA):c.210del (p.Ala71fs) Deletion Pathogenic 88694 rs886037654 2:220366268-220366268 2:219501546-219501546
4 ACTL6A NM_004301.5(ACTL6A):c.1129C>T (p.Arg377Trp) SNV Likely pathogenic 549661 rs868064163 3:179304340-179304340 3:179586552-179586552
5 FAM120AOS NM_198841.4(FAM120AOS):c.743C>T (p.Thr248Ile) SNV Likely pathogenic 183343 rs140119177 9:96209921-96209921 9:93447639-93447639
6 COL5A1 NM_001278074.1(COL5A1):c.608G>T (p.Gly203Val) SNV Likely pathogenic 523328 rs1554781700 9:137593133-137593133 9:134701287-134701287
7 RPS6KA3 NM_004586.3(RPS6KA3):c.533C>G (p.Ala178Gly) SNV Likely pathogenic 374121 rs1057518914 X:20211665-20211665 X:20193547-20193547
8 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met) SNV Likely pathogenic 35609 rs141322087 11:17426099-17426099 11:17404552-17404552
9 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln) SNV Likely pathogenic 523361 rs1344172059 11:17452385-17452385 11:17430838-17430838
10 CPEB1-AS1 NM_001278512.2(AP3B2):c.881A>C (p.Lys294Thr) SNV Uncertain significance 807299 rs200983489 15:83349398-83349398 15:82680646-82680646
11 RYR1 NM_000540.2(RYR1):c.10097G>T (p.Arg3366Leu) SNV Uncertain significance 598974 rs137932199 19:39009932-39009932 19:38519292-38519292
12 SYNE2 NM_182914.2(SYNE2):c.19624G>T (p.Gly6542Trp) SNV Uncertain significance 598975 rs746433383 14:64685197-64685197 14:64218479-64218479
13 ZNF469 NM_001367624.2(ZNF469):c.9532G>A (p.Gly3178Ser) SNV Uncertain significance 523412 rs887755283 16:88503410-88503410 16:88437002-88437002
14 ZNF469 NM_001367624.2(ZNF469):c.470G>A (p.Gly157Glu) SNV Uncertain significance 320853 rs781096189 16:88494348-88494348 16:88427940-88427940
15 ZNF469 NM_001367624.2(ZNF469):c.2569A>G (p.Asn857Asp) SNV Uncertain significance 523411 rs1555518955 16:88496447-88496447 16:88430039-88430039

Expression for Gastroesophageal Reflux

Search GEO for disease gene expression data for Gastroesophageal Reflux.

Pathways for Gastroesophageal Reflux

Pathways related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.36 TP53 IL1B CXCL8
2 9.8 GAST CCK
3 9.32 HRH2 GAST

GO Terms for Gastroesophageal Reflux

Cellular components related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 PYY IL1B GCG GAST CXCL8 COL5A1
2 extracellular region GO:0005576 9.28 PYY MLN IL1B GCG GAST CXCL8

Biological processes related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.23 PYY MLN HRH2 GCG GAST CXCL8
2 regulation of insulin secretion GO:0050796 9.13 IL1B GCG ABCC8

Molecular functions related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 PYY MLN GCG GAST CCK

Sources for Gastroesophageal Reflux

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....